trial · primary record
Rilogrotug
Cachexia; Cancer
| Phase | Phase 2, Phase 3 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 950 |
| Primary completion | 2031-10 |
| Primary endpoint | Phase 2 (A): To evaluate the effect of rilogrotug compared to placebo on weight gain |
| Registry ID | NCT07888075 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-28T13:41:38.323Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT07888075
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.